scholarly journals Poor ovarian response and the possible role of natural and modified natural cycles

2022 ◽  
Vol 16 ◽  
pp. 263349412110620
Author(s):  
Federica Di Guardo ◽  
Christophe Blockeel ◽  
Michel De Vos ◽  
Marco Palumbo ◽  
Nikolaos Christoforidis ◽  
...  

About 20% of women undergoing in vitro fertilization struggle with poor ovarian response, indicating a poor prognosis related to low response following ovarian stimulation. Indeed, poor ovarian response, that is associated with both high cancelation rates and low live birth rates, still represents one of the most important therapeutic challenges in in vitro fertilization. In this context, natural cycle/modified natural cycle– in vitro fertilization, as a ‘milder’ approach, could be a reasonable alternative to high-dose/conventional ovarian stimulation in poor ovarian responders, with the aim to retrieve a single oocyte with better characteristics that may result in a single top-quality embryo, transferred to a more receptive endometrium. Moreover, modified natural cycle– in vitro fertilization may be cost-effective because of the reduced gonadotropin consumption. Several studies have been published during the last 20 years reporting conflicting results regarding the use of natural cycle/modified natural cycle– in vitro fertilization in women with poor ovarian response; however, while most of the studies concluded that mild stimulation regimens, including natural cycle/modified natural cycle– in vitro fertilization, have low, but acceptable success rates in this difficult group of patients, others did not replicate these findings. The aim of this narrative review is to appraise the current evidence regarding the use of natural cycle/modified natural cycle– in vitro fertilization in poor ovarian responders.

2021 ◽  
Vol 15 ◽  
pp. 263349412110242
Author(s):  
Liese Boudry ◽  
Annalisa Racca ◽  
Herman Tournaye ◽  
Christophe Blockeel

Infertile patients with a diminished ovarian reserve, also referred to as poor ovarian responders, constitute a substantial and increasing population of patients undergoing in vitro fertilization. The management of patients with poor ovarian response is still a controversial issue. Almost a century has passed since the introduction of the first gonadotropin. A broad collection of urinary and recombinant gonadotropins, including biosimilars, is commercially available now. Despite great advances in assisted reproductive technology, there remains uncertainty about the optimal treatment regimen for ovarian stimulation in poor ovarian responders. Although oocyte donation is the most successful and ultimate remedy for poor ovarian responders, most patients persist on using their own oocytes in several attempts, to achieve the desired pregnancy. The aim of this review is twofold: first, to provide an overview of the commercially available gonadotropins and summarize the available evidence supporting the use of one or another for ovarian stimulation in poor ovarian responders, and second, to address the controversies on the dosage of gonadotropins for this specific in vitro fertilization population.


2015 ◽  
Vol 103 (6) ◽  
pp. 1469-1476.e3 ◽  
Author(s):  
Cengiz Karakaya ◽  
Ozlem Guzeloglu-Kayisli ◽  
Asli Uyar ◽  
Amanda N. Kallen ◽  
Elnur Babayev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document